
|Articles|September 7, 2012
Safety Tolerability footer references
Advertisement
References 1. Data on File, 309560. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 2. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with
fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer [published errata
appears in
J Clin Oncol.
2011;29(16):2293]
J Clin Oncol
. 2010;28(30):4594-4600. 3. FASLODEX [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Exploring The Impact of ADTs on Cardiac Risk in Prostate Cancer Treatment
3
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
4
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
5



































